REVAMP: Management Guided by Genotypic Resistance Testing Following First-line ART Failure Comparable to Viral Load–Guided Management in Sub-Saharan Africa

March 6-10, 2021; Virtual
Study finds that use of genotypic resistance testing to guide management of patients experiencing first-line ART failure does not improve viral suppression rates, highlighting need for alternative strategies to improve management of ART failure.
Format: Microsoft PowerPoint (.ppt)
File Size: 183 KB
Released: March 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, and comorbidities

Jeffrey Kwong, DNP, MPH, FAANP, FAAN Released: September 23, 2022

Clinical Care Options (CCO) expert analysis of new data from AIDS 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: September 20, 2022

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Released: September 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings